In addition to accompanying CDKN2A HD, there are also publications indicating that MTAP inactivation contributes to gliomagenesis through epigenetic mechanisms, especially in glioblastomas (30); thus, MTAP may be a target for treatment (30, 31). This evidence concerns the gene CDKN2A and glioblastoma.